MedX Granted Patent for Bone Healing

Announced earlier today, MedX Health Corp. has received a Notice of Allowance by the USPTO for its MedX Laser and Light Probe.  This device can be used for bone healing, bone growth stimulation and bone cartilage regeneration.  MedX claims their probe can be used to help those that currently suffer from carpal tunnel syndrome, tendonitis, rheumatoid arthritis, and wound healing.

The Laser and Light Probe will promote healing by triggering biological changes within the body, as well as stimulating and accelerating cellular metabolic processes.  MedX claims that utilizing their probe will increase the circulation by forming new capillaries, and stimulating collagen protein production.  Thus, healing would be accelerated by damaged bone and tissue cells being replaced more rapidly.

“This notice of allowance from the U.S. Patent & Trademark Office broadens our device portfolio,” states Steve Guillen, president and CEO of MedX Health. “It is another important step toward our entry into the wound healing market, which we expect will take place this year,” adds Guillen.

Cytori Patent Allows Inclusion of Stem Cells

The United States Patent and Trademark Office has granted Cytori Therapeutics a Notice of Allowance, which expands the company’s protection of their Celution System.  In a press release, the company states that the patents contain over 40 claims, the most notable being the following: alternative Celution system configurations beyond those already covered in patents; expanded protection for cosmetic and reconstructive surgery applications; and technology within the device that optimizes intravascular delivery of adipose-derived stem and regenerative cells.

Cytori has already achieved significant breakthroughs in the field of regenerative medicine.  Their Celution 800 system is currently being introduced to Europe for reconstructive surgery, while the Celution 900 system is being commercialized globally for cryopreserving a patient’s own stem and regenerative cells.  Yet, the claims in the new patent also expand the array of Celution output compositions, so that combinations of cells, matrices, and other specific needs would also be protected.  Furthermore, the claims related to intravascular delivery could potentially broaden the Celution System output, to help those with cardiovascular disease, liver disease, and renal failure.

Cytori’s intellectual property portfolio contains nine U.S. and international patents, and over 120 applications pending worldwide.  These patents are related to the devices, methods, and uses of adipose-derived stem and regenerative cells.

Mylan Inc. Issued Patents for COPD

Mylan Inc. announced this morning that they have been issued several U.S. patents which cover the administration of a ready-to-use inhaler.  Mylan stated in a press release that the patents were directly granted to its subsidiary, Dey L.P., and that the company received a “Notice of Allowance” on another patent which they expect to be granted in the near future.

The issued patents protect Dey’s Perforomist Inhalation Solution, which is a treatment for chronic obstructive pulmonary disease.  Two of the patents are directed towards the compositions of “R-formoterol,” a specific form of the formoterol molecule, and its use.  Another patent covers the administration of formoterol in a storage stable composition.  These patents extend to the year 2021.

Once the patent is granted that received a “Notice of Allowance,” Dey will possess seven patents directed towards the composition and use of formoterol.  Dey also has additional patents pending directed to formoterol-containing compositions and their use in the treatment of respiratory conditions.